GHTF (Global Harmonisation Task Force) issues global guidelines on vigilance exchange and auditing
This article was originally published in Clinica
Two key documents encouraging global convergence of medical devices rules, concerning vigilance and auditing, have been issued by the Global Harmonisation Task Force. Known as "final" documents, these have been endorsed at a GHTF plenary session, which means that all five founding members of the GHTF (Australia, Canada, the EU, Japan and the US) are committed to adopting/implementing them.
You may also be interested in...
The consensus among investors is that medtech has been the best-performing part of health care for the past three to four years, and investment levels remain good. Seemingly all-encompassing of late has been companies’ preoccupation with digital strategies, but there is a lot more to this unique industry than just digital.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Bangladesh’s Beximco will market Mylan’s biosimilars in its domestic market, under a deal that has just been struck between the two companies. The Ogivri trastuzumab biosimilar, co-developed by Mylan and Biocon, will be the first product launched as part of the collaboration.